CS Paper Radar

An auditable conditional-strategy framework for open-ended decision-making in complex lung cancer

Daoyun Wang, Zhicheng Huang, Huaiyuan Sun, Jiaqi Xu, Xiaowei Xu, Zhibo Zheng, Zhongxing Bing, Yuxiao Lin, Yicheng Liang, Chao Gao, Bowen Xue, Kai Zhang, Song Xu, Wanpu Yan, Hui Xia, Lin Li, Xiang Yan, Mu Hu, Qianli Ma, Zhiqiang Xue, Xiaofang Liu, Zhihai Han, Nan Zhang, Chuanhao Tang, Tongmei Zhang, Lan Song, Zhaohui Zhu, Xuan Zeng, Shafei Wu, Hui Guan, Lei Deng, Huaxia Yang, Zeliang Lian, Wubin Sun, Yongxin Wang, Xiaohui Shen, Binlin Wang, Tiantian Gu, Yu Cui, Li Zhang, Shirui Wang, Naixin Liang

cs.AI ·submitted 2026-09-24 11:08 UTC · v2

Abstract

Complex lung cancer decisions can involve several defensible pathways whose eligibility, sequencing and safety depend on unresolved information. Effective support must make explicit how patient conditions govern pathway eligibility, deferral and redirection. MedGPT Clinical Explorer (MCE) organizes alternatives, decision-changing unknowns, safety constraints and fallback into a conditional strategy for clinician review. To evaluate this representation in physician-authored strategies, multidisciplinary experts established case-specific references for 40 cases within a purposive 100-case corpus, and 250 physicians from 98 institutions produced 2,250 strategies under unaided, retrieval-reference and MCE-assisted conditions. MCE-assisted strategies expressed more applicable clinical requirements, measured by the Admissible Pathway Attainment Score (APAS; 0-100), than unaided strategies (adjusted difference, 12.87; 95% CI, 11.18-14.55) and retrieval-reference strategies (5.22; 3.52-6.93). With the same knowledge base available in the retrieval-reference and MCE-assisted conditions, the additional content centered on candidate pathways, decision-critical information and safety constraints. Physicians' whole-strategy acceptability judgments correlated with APAS (Spearman's rho = 0.671), while a complementary relationship audit assessed whether candidates, conditions and subsequent actions were coherently connected. Together, these findings identify two complementary dimensions of open-ended decision support: coverage of clinically relevant content and coherent links among pathways, conditions and subsequent actions. MCE provides a shared decision object that makes consequential omissions and pathway contingencies visible before action; prospective studies should evaluate its effects on clinical workflow and patient outcomes.

Closest papers

Nearest neighbours by meaning across the whole index.

Disentangling Lung-Cancer CT/LDCT AI: A Systematic Evidence Map of Clinical Tasks, Evidence Chains, and Translational Gaps

cs.LG ·2026-09-28 ·Surajit Das
similarity 0.68
Abstract

Artificial-intelligence studies using computed tomography (CT) for lung cancer are often broadly labelled "prediction" despite addressing clinically distinct tasks. We systematically mapped CT/low-dose CT (LDCT)-centered lung-cancer AI using five-database retrieval, full-text eligibility assessment, role-aware modality/omics extraction, clinical-task classification, and a Multi-Tier Evidence Graph (MTEG). The final corpus comprised 293 studies (2016-2026): 230 Detection, 8 future Risk-prediction, and 55 Other studies. Clinical variables (96.2%), 3D CT/LDCT (73.0%), and radiomics (63.5%) predominated, whereas external validation (29.0%), calibration (20.5%), decision-curve analysis (13.0%), longitudinal CT (17.7%), and saliency/attribution XAI (21.5%) were less frequent. The MTEG comprised 377 nodes and 3,444 edges; only 31 studies (10.6%) completed the six-tier substantive evidence chain, with greatest attrition at reasoning/explanation. Overall, the literature is detection-dominated, genuine future risk prediction remains uncommon, and complete translational evidence chains are rare.

0.08

Patient-specific rubric-based evaluation of large language models across longitudinal cancer care

cs.AI ·2026-10-26 ·Wei-Wei Zhang, Pengkai Wang, Yan Li, Zhijie Sang, Guan-Qun Zhou +11 more
benchmark similarity 0.62
Abstract

Large language models (LLMs) show promise in specialty medicine, yet existing evaluations largely focus on isolated clinical encounters rather than tracking how clinical responsibilities evolve across a longitudinal care pathway. Here we introduce NPC-RubricBench, a phase-aware benchmark for evaluating multistage clinical reasoning across the cancer care continuum, using nasopharyngeal carcinoma as a defined disease context. Curated from longitudinal records of 405 patients across two cancer centers, the benchmark comprises 941 patient-phase units across six sequential care phases and 17,688 patient-specific atomic criteria spanning five evaluation dimensions, with each assessment strictly restricted to decision-time clinical evidence. Evaluating 30 general-purpose and medical LLMs revealed that strong diagnostic performance does not carry over to downstream care. We evaluated 30 general-purpose and medical LLMs, showing that high diagnostic performance did not translate into improved downstream care. Instead, the dominant failure modes reversed across phases. Explicit decision errors dominated anatomical staging at 48.2%, whereas decision omissions dominated initial work-up and post-treatment follow-up at 33.4% and 30.4%, respectively. In the evaluated model set, medically adapted models showed higher omission rates than general-purpose models. Moreover, varying query granularity exposes a critical specification trade-off: broad open-ended requests degrade Decision Quality across all 30 models, while more detailed, checklist-like prompts raise Decision Quality but reduce Evidence Faithfulness and Safety Adherence. Furthermore, NPC-RubricBench demonstrates that static diagnostic benchmarks are insufficient to ensure consistent clinical reliability over time, highlighting the importance of phase-adaptive safeguards in multistage medical AI.

0.46

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

cs.AI cs.LG ·2026-10-01 ·Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
publishedbenchmarkcode/data similarity 0.61
Abstract · Accepted for oral presentation and publication at the Pacific Symposium on Biocomputing (PSB) 2027

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

0.56

LUCQUE: A lung cancer screening dataset from Québec for reliable AI evaluation

cs.DB cs.AI ·2026-11-09 ·Johanna Topalis, Yannick Lemaréchal, Gabriel Couture, Hanife Ersay, Loran Nas +5 more
similarity 0.60
Abstract

BACKGROUND: AI-based tools are expected to play a key role in lung cancer screening (LCS). The evaluation of these tools often relied on private datasets or fragmented public datasets with inconsistent availability of clinical data and expert nodule annotations. This has hindered reproducibility, comparability, and independent assessment of AI tools. To address these gaps, we present LUCQUE, a novel, large, comprehensively annotated dataset derived from LDCT lung cancer screening in Québec, which is accessible for reliable AI evaluation. METHODS: LUCQUE was curated and is hosted on PARADIM, a digital infrastructure supporting DICOM data de-identification, annotation, long-term storage and analysis. LDCT scans and clinical information were combined to a curated collection and complemented by voxel-level, expert-derived pulmonary nodule and cyst segmentations, and Lung-RADS-based lesion characteristics. Key dataset characteristics and statistics were reported, including participant demographics, imaging parameters, radiological findings, and segmented lesion characteristics. Dataset analyses were conducted according to PARADIM's model-to-data approach, in which user code is executed on the platform such that data remains on premise. RESULTS: LUCQUE currently comprises 1,678 LDCT baseline studies from 1,678 participants. Most studies were classified as Lung-RADS 2. A total of 1,776 pulmonary nodules and 60 cysts were annotated, with a median (interquartile range) volume of $89\,(56,\,159)\,\mathrm{mm}^3$ and $1,384\,(589,\,3793)\,\mathrm{mm}^3$ respectively. CONCLUSIONS: Compared to publicly available LCS datasets, LUCQUE currently represents the largest accessible annotated real-world LCS dataset. Access to LUCQUE is provided via a model-to-data approach, enabling privacy-preserving, reproducible, and independent real-world evaluation of AI tools in LCS.

0.18

Towards AI-Assisted Clinical Trial Matching: Practical Considerations, Multicenter Evaluation, and Real-World Deployment

cs.CL cs.AIcs.CY ·2026-09-01 ·Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer +22 more
benchmark similarity 0.60
Abstract · 43 pages, 12 figures

Clinical trials are essential for evidence-based medicine and drug development, but many fail because of insufficient patient enrollment. Although there is growing interest in using AI to support patient recruitment, existing systems largely perform eligibility assessment alone and have rarely been evaluated in real-world workflows. Here we present TrialGPT 2.0, an AI-assisted clinical trial recommendation system improved for responsible real-world deployment. Rather than asking only whether a patient may qualify, the system assesses which trials warrant further consideration given the patient's current clinical needs and local workflow priorities, and provides structured, inspectable explanations for expert review. Importantly, we evaluated TrialGPT 2.0 retrospectively and prospectively across government research, patient-advocacy, academic medical center, and community-based radiation-oncology settings. In retrospective multicenter cohorts comprising 288 cases, TrialGPT 2.0 retrieved at least one clinician-recommended trial in its top 10 recommendations for approximately 91% of cases while reducing clinician screening time by 55.0%. In a six-month prospective evaluation embedded in an active precision oncology tumor board, TrialGPT 2.0 contributed additional trial opportunities missed by the routine workflow, increasing the number of patient cases with at least one final trial recommendation by 90.9%. To support scientific reproducibility, we also developed NIH-TrialBench, a clinician-authored benchmark comprising 126 diverse synthetic patient vignettes and matching scenarios from 11 NIH Institutes and Centers. Together, these findings support the value of AI to assist clinical trial matching by improving clinician efficiency and identifying frequently overlooked trial opportunities, ultimately helping to expand and accelerate accrual to cancer trials.

0.24

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

cs.AI ·2026-10-30 ·Russell Ro, Reza Abbasi-Asl
top venuebenchmark similarity 0.59
Abstract · 18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). …

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

0.55

Temporal Evidence Allocation For Longitudinal Clinical Retrieval: A Position And Technical Report

cs.AI ·2026-10-20 ·Soumya Ranjan Sahoo, Divya Bharti, Sanand Sasidharan
publishedposition similarity 0.59
Abstract · Extended report of our accepted abstract at IEEE BHI 2026

Electronic health records are written to support care, not retrieval. Across years of oncology notes, the primary diagnosis is restated in report after report, while the events that shape a patient's course, such as a recurrence or a change in therapy, may be recorded only once. A retriever that ranks passages by similarity to the query keeps returning the repeated material and can miss these transitions, that is, it exhibits temporal redundancy across historical narratives. We argue that longitudinal clinical retrieval should be treated as allocating a limited evidence budget across time, not just ranking by relevance. We separate the task into three objectives: temporal evidence allocation, candidate reconstruction, and clinical validation. In Study A (13 clinical queries over 20 patient records, with two-stage reconstruction), the Temporal-15 configuration reaches a milestone slot recall of 0.538, compared with 0.388 for the Global-50 baseline. However, it also retrieves far more evidence (496 versus 50 indexed units per query), so the gain cannot be credited to allocation alone. When evidence is held fixed, removing prompted precedence rules raises schema-order reversals from 0.010 to 0.080. A five-patient, single-query pilot with fixed budgets finds that wider temporal coverage does not reliably yield more dated milestones. Together, these results suggest that how much a record says about a period is a poor guide to how useful that period is as evidence. Because no expert reference timelines are available, our measurements describe retrieval behavior rather than clinical accuracy. This position and technical report presents the retrieval analysis behind the Onco-CONSTRUE framework and sets out a research agenda for budget-constrained longitudinal clinical retrieval.

0.29

Scaling large language model-assisted line-of-therapy adjudication with human-in-the-loop evidence-calibrated selection

cs.LG q-bio.QMstat.AP ·2026-11-15 ·Olatunji Oni, Sanhita Sengupta, Marc De Benedetti, Nathanial Eddy
similarity 0.57
Abstract · 12 pages, 4 figures

Large language models (LLMs) have enabled the ability to scale clinical adjudication tasks traditionally dependent on exhaustive manual review. Line-of-therapy (LoT) adjudication, a major bottleneck in oncology cohort construction, is a prime example. Line boundaries must be inferred from longitudinal treatment histories according to nuanced, study-specific definitions, at every regimen transition for every patient. LLMs can apply this adjudication at scale, but their reliability varies across patients. Treatment histories differ in complexity, and ambiguous or atypical patterns depend on expert clinical judgment. Reliable automation thus requires verified support for model assignments and the ability to identify cases that warrant manual review. Here, we present evidence-calibrated selection (ECS), a human-in-the-loop framework for scaling LLM-assisted LoT adjudication. ECS derives confidence from observed clinician adjudications, prioritizes patients with the least-supported assignments for follow-up review, and returns completed adjudications to the model as precedent. As the evidence base grows, ECS continuously calibrates confidence to estimate residual error, thus enabling more efficient use of clinician time. In simulations on 136 clinician adjudicated patients with multiple myeloma, ECS achieved a residual error of 5% after review of 44.6% of patients, compared to 62.2% when review was directed by LLM self-reported confidence and 81.9% under random sampling. These results support a scalable approach to study-specific LoT adjudication, using clinician evidence to inform automated predictions, minimize error, and reduce review burden.

0.21